Semax
Also known as: ACTH(4-10) analogue, ACTH(4-7)PGP, Met-Glu-His-Phe-Pro-Gly-Pro, MEHFPGP, Semax peptide, ACTH4-7-Pro-Gly-Pro
Synthetic nootropic/neuroprotective heptapeptide; melanocortin-related peptide; ACTH analogue
What it is
Semax is a neuroprotective peptide approved in Russia for stroke treatment and cognitive decline, widely used in the nootropics community for focus, memory, and mood. It supports the production of nerve growth factors and protects brain cells from damage. Approved in Russia; not FDA-approved; evidence includes Russian clinical trials and animal studies.
The scientific side
Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide analogue of the N-terminal ACTH(4-10) fragment that is devoid of hormonal activity. Its documented or proposed mechanisms include: (1) upregulation of NGF and BDNF gene expression in the hippocampus, frontal cortex, and retina; (2) modulation of GABA-activated ionic currents (potentiation in cerebellar Purkinje cells) and inhibition of glycine-activated chloride currents in hippocampal pyramidal neurons; (3) modulation of intracellular calcium dynamics in hippocampal pyramidal neurons; (4) suppression of proinflammatory gene expression (Il1a, Il1b, Il6, Ccl3, Cxcl2) and activation of neurotransmission-related genes under ischemic conditions (PMID 34097675; PMID 32580520); (5) high-affinity chelation of Cu(II) ions, enabling extraction of copper from Cu-Aβ complexes and reduction of associated ROS production (PMID 40496623; PMID 35080861); (6) inhibition of enkephalin-degrading enzymes in human serum (IC50 10 µM); (7) modulation of brain functional connectivity, particularly affecting the default mode network and amygdala–temporal cortex connectivity (PMID 30225715; PMID 32342318); (8) targeting the µ-opioid receptor (Oprm1), regulating USP18 and deubiquitination of FTO to promote lysosomal membrane stability after spinal cord injury; (9) regulation of VEGF family gene expression in ischemic brain tissue (PMID 22772900; PMID 23888777); (10) immunomodulatory effects via immune response gene expression changes (PMID 24661604; PMID 42021992); (11) antioxidant properties demonstrated by counteracting heavy metal-induced learning inhibition. Metabolically, Semax is cleaved into functional fragments (HFPGP, PGP) that form a "synacton" with distinct receptor binding characteristics.
Class: Synthetic nootropic/neuroprotective heptapeptide; melanocortin-related peptide; ACTH analogue
Modified Forms
The following chemical variants are structurally derived from this peptide. They are documented here rather than on separate pages.
N-Acetyl Semax Amidate
N-Acetyl Semax Amidate adds an N-acetyl group at the N-terminus and an amide group at the C-terminus of the Semax sequence. Both modifications inhibit enzymatic degradation, extending the peptide's biological half-life compared to standard Semax. No peer-reviewed pharmacological or clinical studies specific to this modified form were found in literature searches — all mechanism and efficacy claims are extrapolated from Semax research. Community users often report using it at lower doses than standard Semax under the assumption of greater potency from increased stability, though this assumption lacks published experimental support. Regulatory status is identical to Semax: not approved in any reviewed jurisdiction.
How dosing differs: Community protocols report 100–300 mcg intranasal, often lower than standard Semax (500–600 mcg) due to assumed potency difference from increased enzymatic stability. No published dose-finding data exists for this modified form.
Key differences from parent: N-terminal acetylation + C-terminal amidation increase resistance to peptidase cleavage. Half-life is assumed longer than standard Semax but has not been measured in published studies. No independent mechanism or efficacy studies exist.
Administration & storage
- Administration
- Intranasal administration (nasal drops) — human and animal studies (PMID: 12459874302257152280313222708068)Endonasal electrophoresis — human optic nerve disease study (PMID: 10741256)Intraperitoneal injection — animal studies (PMID: 3944274633459919327377232857709725464761)Neonatal injection (route not further specified) — neonatal mouse study (PMID: 19145359)
- Storage
- No storage conditions for Semax are described in the reviewed abstracts.
- Cautions
- Clinical use has been primarily documented in Russian literature; long-term safety data and large-scale randomized controlled trials are lacking for most indications.,One study in 187 cerebrovascular insufficiency patients reported minor side effects and good tolerability including in older patients, but specific adverse events were not detailed in the available abstract.,Neonatal Semax injection in mice reduced epilepsy susceptibility in one strain (DBA/2J) but not others, indicating strain/population-specific effects that may not generalize.,The free N-terminal amino group of Semax appears critical for copper-related cytoprotective activity; N-terminal acetylation (Ac-Semax) did not protect neuroblastoma cells from Cu(II)-induced toxicity.,Sterile technique is essential for any injectable or intranasal preparation to prevent contamination.
Legal & regulatory status
Not stated in reviewed literature — requires manual verification
Not stated in reviewed literature — requires manual verification
Not stated in reviewed literature — requires manual verification
What it's studied for
- Ischemic stroke — neuroprotection and functional recovery Mixed
- In 110 post-ischemic stroke patients, semax (6000 mcg/day x 10 days, 2 courses with 20-day interval) increased plasma BDNF levels and accelerated Barthel index improvement regardless of rehabilitation timing. PMID 29798983 Gusev et al. (2018). Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.
- In 30 acute hemispheric ischemic stroke patients, Semax combined with conventional therapy improved regression of neurological deficits; most effective doses were 12 mg/day (moderate stroke) and 18 mg/day (severe stroke) for 5–10 days. PMID 11517472 Gusev et al. (1997). Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.
- RNA-Seq in rat tMCAO model showed Semax suppressed inflammation-related genes and activated neurotransmission-related genes at 24 h after ischemia-reperfusion. PMID 32580520 Filippenkov et al. (2020). Genes.
- In rat tMCAO model, Semax upregulated active CREB, downregulated MMP-9, c-Fos, and active JNK at 24 h, consistent with suppression of inflammation/cell death and activation of recovery. PMID 34201112 Sudarkina et al. (2021). International Journal of Molecular Sciences.
- Genome-wide transcriptional analysis in rat pMCAO model showed Semax predominantly enhanced expression of immune-response genes and vascular-system genes at 3 and 24 h after occlusion. PMID 24661604 Medvedeva et al. (2014). BMC Genomics.
- In rat global ischemia model, Semax increased proliferation of neuroglia, blood vessel endothelium, and progenitor cells in subventricular zone, and abated manifestation of ischemic damage. PMID 20617398 Stavchansky et al. (2011). Journal of Molecular Neuroscience.
- Cerebrovascular insufficiency — disease progression prevention Human observational
- In 187 patients with cerebrovascular insufficiency, Semax treatment resulted in significant clinical improvement, disease stabilization, and reduced risk of stroke/TIA, with minor side effects and good tolerability including in older patients. PMID 15792140 Gusev et al. (2005). Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.
- Optic nerve disease and glaucomatous optic neuropathy Human observational
- Semax administered intranasally or by endonasal electrophoresis improved visual acuity, visual field, optic nerve electrical sensitivity/conductivity, and color vision in patients with optic nerve diseases. PMID 10741256 Polunin et al. (2000). Vestnik oftalmologii.
- Neuroprotective therapy including semax showed advantages over traditional treatment for glaucoma patients with normalized intraocular pressure, attributed to semax's neuroprotective and neurotrophic effects. PMID 11569188 Kurysheva et al. (2001). Vestnik oftalmologii.
- Peptic ulcer — adjunct healing Human observational
- Intranasal Semax (1% solution, 2–4 drops 3 times/day for 10 days) combined with standard antiulcer therapy resulted in ulcer healing in 89.5% of patients by day 14, vs. 30.8% in controls. PMID 12459874 Ivanikov et al. (2002). Bulletin of Experimental Biology and Medicine.
- Alzheimer's disease — amyloid aggregation inhibition and cognitive improvement Mixed
- In artificial membrane models, Semax prevented formation of Aβ:Cu complexes and exhibited anti-aggregating and cytoprotective properties, particularly in the presence of Cu²⁺. PMID 35080861 Sciacca et al. (2022). ACS Chemical Neuroscience.
- Semax extracted Cu(II) from Cu-Aβ species, reduced redox cycling and ROS production in vitro, and showed cytoprotective properties for SH-SY5Y cells. PMID 40496623 Tomasello et al. (2025). Bioinorganic Chemistry and Applications.
- In APPswe/PS1dE9/Blg transgenic Alzheimer's disease mice, Semax improved cognitive functions (open field, novel object recognition, Barnes maze) and reduced amyloid inclusions in cortex and hippocampus. PMID 41479572 Radchenko et al. (2025). Acta Naturae.
- Spinal cord injury — functional recovery Animal studies only
- Semax improved functional recovery in female C57BL/6 SCI mice, inhibited LMP-related pyroptosis, decreased oxidative stress, regulated USP18 via µ-opioid receptor targeting, and promoted deubiquitination of FTO. PMID 40692165 Liu et al. (2025). British Journal of Pharmacology.
- Antidepressant / antistress effects Animal studies only
- In male rats with chronic unpredictable stress, daily intraperitoneal Semax (60 nmol/kg BW) reversed CUS-induced anhedonia, body weight gain suppression, adrenal hypertrophy, and decreased hippocampal BDNF levels. PMID 39442746 Inozemtseva et al. (2024). European Journal of Pharmacology.
- Semax attenuated effects of chronic unpredictable stress in rats (no abstract text available beyond title/MeSH). PMID 24385169 Yatsenko et al. (2013). Doklady Biological Sciences.
- Nootropic effects — learning and memory Mixed
- Semax counteracted heavy metal-induced inhibition of avoidance conditioning in rats, comparable in effect to ascorbic acid, confirming antioxidant/nootropic properties. PMID 27411820 Inozemtsev et al. (2016). Doklady Biological Sciences.
- Intraperitoneal Semax (0.05 mg/kg) accelerated acquisition of one-way active avoidance and stimulated avoidance restoration after functional disturbances in shuttle-box in rats. PMID 25464761 Inozemtsev et al. (2013). Zhurnal vysshei nervnoi deiatelnosti.
- Intranasal 1% Semax in healthy volunteers produced a greater volume of the default mode network rostral subcomponent vs. placebo on resting-state fMRI at 5 and 20 min post-administration. PMID 30225715 Lebedeva et al. (2018). Bulletin of Experimental Biology and Medicine.
- In 52 healthy participants, Semax and Selank showed distinct and general effects on functional connectivity between right amygdala and right temporal cortex on resting-state fMRI. PMID 32342318 Panikratova et al. (2020). Doklady Biological Sciences.
- Attention-deficit hyperactivity disorder (ADHD) and Rett syndrome — hypothesized therapeutic potential Animal studies only
- Hypothesis paper proposing Semax as a potential ADHD and Rett syndrome therapy based on its ability to augment dopamine release, stimulate central BDNF synthesis, improve selective attention, and modulate brain development in animal studies. PMID 16996699 Tsai (2007). Medical Hypotheses.
- Parkinson's disease — behavioral effects Animal studies only
- In 6-OHDA rat PD model, Semax did not affect motor activity or passive defensive behavior; Selank (but not Semax) decreased anxiety in elevated cross-shaped maze. PMID 28702721 Slominsky et al. (2017). Doklady Biological Sciences.
- Audiogenic epilepsy — neonatal intervention Animal studies only
- Neonatal injection of Semax (days 2–7 of life) significantly reduced predisposition to audiogenic epilepsy in one-month-old DBA/2J mice. PMID 19145359 Boyarshinova et al. (2008). Bulletin of Experimental Biology and Medicine.
- Neonatal stress / maternal deprivation — behavioral correction Animal studies only
- Intranasal Semax (0.05 mg/kg, postnatal days 15–28) weakened impact of maternal deprivation on body weight and normalized anxiety levels in adolescent rats. PMID 22803132 Volodina et al. (2012). Bulletin of Experimental Biology and Medicine.
- Intranasal Semax (50 µg/kg, postnatal days 15–28) after neonatal isolation reduced metabolic dysfunction and normalized corticosterone stress response in white rats. PMID 22708068 Volodina et al. (2012). Acta Naturae.
- Immunomodulation Animal studies only
- Semax acted as an effective immune corrector in a social stress model, restoring cellular and humoral immunogenesis reactions and phagocytic activity of neutrophils in rats. PMID 31028579 Samotrueva et al. (2019). Bulletin of Experimental Biology and Medicine.
- Stress-induced gastrointestinal and hepatic protection Animal studies only
- Intraperitoneal ACTH(4-7)PGP (Semax) (5, 50, 150, 450 µg/kg) before restraint stress reduced corticosterone, alleviated colon wall pathomorphological changes, and promoted intestinal adaptation in rats. PMID 33459919 Svishcheva et al. (2021). Bulletin of Experimental Biology and Medicine.
- Intraperitoneal Semax (5, 50, 150, 450 µg/kg) in chronic emotional and painful stress normalized hepatocyte protein synthesis function and serum ALT activity in rats in a dose-dependent manner. PMID 28577097 Ivanov et al. (2017). Bulletin of Experimental Biology and Medicine.
- Early-life SSRI exposure — behavioral and neurochemical correction Animal studies only
- Semax administration (postnatal days 15–28) after neonatal fluvoxamine exposure reduced anxiety-like behaviour, improved learning, and normalized brain biogenic amine levels in rats. PMID 33418449 Glazova et al. (2021). Neuropeptides.
- Neurodegenerative disease (general) — oxidative stress and neuroinflammation modulation Mixed
- Review: Semax identified among bioactive peptides modulating oxidative stress, neuroinflammation, mitochondrial preservation, and synaptic plasticity in neurodegenerative disease models. PMID 41004910 Giri & Chandra (2025). Neuropeptides.
Safety signals
- Minor side-effect profile reported in 187 patients with cerebrovascular insufficiency; well-tolerated including in older age groups — specific adverse events not detailed in abstract PMID 15792140
- N-terminal acetylation of Semax (Ac-Semax) did not protect SH-SY5Y neuroblastoma cells from Cu(II)-induced cytotoxicity, unlike parent Semax — suggesting modification may alter safety/efficacy profile PMID 27586814
- Neonatal Semax injection had strain-specific effects on audiogenic epilepsy susceptibility in mice; no effect in 4 of 5 strains tested PMID 19145359
- Non-approved peptide with limited long-term safety data and absence of systematic clinical validation noted in narrative review PMID 42021992
Protocol
300 mcg intranasal, once daily. Cycle: 2-4 weeks on, 1-2 weeks off.
About these dose ranges
Dose ranges below reflect commonly reported community protocols. Where published research cites a specific dose, the PMID is linked. Doses without citations are not clinical recommendations — they reflect what practitioners and researchers commonly report using.
Community-reported dosing
| Route | Dose | Frequency / Duration | Population / context | Source tier |
|---|---|---|---|---|
| Not specified (standard regimen) | 6000 mcg/day | 10 days per course; 2 courses with 20-day interval | human | Research PMID 29798983 |
| Not specified | 12 mg/day (moderate stroke); 18 mg/day (severe stroke) | 5–10 days | human | Research PMID 11517472 |
| Intranasal | 1% solution, 2–4 drops 3 times a day | 10 days | human | Research PMID 12459874 |
| Intranasal | 1% Semax (single administration) | Single dose; fMRI at 5 and 20 min post-injection | human | Research PMID 30225715 |
| Intranasal | 0.05 mg/kg | Postnatal days 15–28 (daily) | animal | Research PMID 22803132 |
| Intranasal | 50 µg/kg | Postnatal days 15–28 (daily) | animal | Research PMID 22708068 |
| Intraperitoneal | 60 nmol/kg of body weight | Daily during chronic unpredictable stress protocol | animal | Research PMID 39442746 |
| Intraperitoneal | 5, 50, 150, and 450 µg/kg | Single administration 12–15 min before restraint stress modeling | animal | Research PMID 33459919 |
| Intraperitoneal | 5, 50, 150, 450 µg/kg | 12–15 min before chronic restraint stress sessions | animal | Research PMID 32737723 |
| Intraperitoneal | 5, 50, 150, and 450 µg/kg | Chronic emotional and painful stress model | animal | Research PMID 28577097 |
| Intraperitoneal | 5, 50, 150, 450 µg/kg | Single administration before restraint stress | animal | Research PMID 38459919 |
| Intraperitoneal | 0.05 mg/kg | Single administration (avoidance conditioning sessions) | animal | Research PMID 25464761 |
| Bath application (brain slice) | 1 µM (in vitro/ex vivo slice preparation) | Single application to brain slices | animal | Research PMID 41171324 |
| Perfusion solution (in vitro) | 0.1 µM and 1 µM | Single application (concentration-clamp experiment) | animal | Research PMID 29577196 |
| In vitro | IC50 10 µM | In vitro assay | in_vitro | Research PMID 11443939 |
| intranasal | 300 mcg | once daily · 2-4 weeks on, 1-2 weeks off | biohackers and nootropic users seeking cognitive enhancement | [Community] |
| intranasal | 600 mcg | once daily · 2-4 weeks on, 1-2 weeks off | experienced biohackers and nootropic users | [Community] |
| intranasal | 900 mcg | once daily · 2-4 weeks on, 1-2 weeks off | experienced biohackers comfortable with nootropic peptides | [Community] |
| intranasal | 300 mcg | twice daily (morning and midday) · 2-4 weeks on, 1-2 weeks off | biohackers optimizing for sustained daily cognitive output | [Community] |
| intranasal | 600 mcg | twice daily (morning and midday) · 2-4 weeks on, 1-2 weeks off | experienced nootropic users seeking maximal daily cognitive enhancement | [Community] |
| subcutaneous injection | 50 mcg | once daily · 2-4 weeks on, 1-2 weeks off | biohackers preferring injectable administration for enhanced bioavailability | [Community] |
| subcutaneous injection | 100 mcg | once daily · 2-4 weeks on, 1-2 weeks off | biohackers using injectable peptides for cognitive or neuroprotective purposes | [Community] |
| subcutaneous injection | 200 mcg | once daily · 2-4 weeks on, 1-2 weeks off | experienced injectable peptide users seeking stronger cognitive or neuroprotective effects | [Community] |
| intranasal | 600 mcg | once daily, taken acutely before demanding cognitive tasks · as-needed / acute use (no structured cycle) | students, professionals, and biohackers using Semax situationally | [Community] |
| intranasal | 300 mcg | once daily · 4-8 weeks continuous | users with anxiety, depression, or seeking mood stabilization alongside cognitive benefits | [Community] |
| intranasal | 600 mcg | once daily · 4-8 weeks on, 2-4 weeks off | biohackers stacking Semax with Selank for synergistic nootropic and anxiolytic effects | [Community] |
| intranasal | 900 mcg | once daily · 5 days on, 2 days off (weekday cycling) | professionals and students using Semax as a weekday cognitive enhancer | [Community] |
Blends containing this peptide
All studies (42)
- PMID 10741256 Human observational
Optic nerve disease and glaucomatous optic neuropathy - PMID 11569188 Human observational
Optic nerve disease and glaucomatous optic neuropathy - PMID 12459874 Human observational
Peptic ulcer — adjunct healing - PMID 15792140 Human observational
Cerebrovascular insufficiency — disease progression prevention - PMID 11517472 Mixed
Ischemic stroke — neuroprotection and functional recovery - PMID 20617398 Mixed
Ischemic stroke — neuroprotection and functional recovery - PMID 24661604 Mixed
Ischemic stroke — neuroprotection and functional recovery - PMID 25464761 Mixed
Nootropic effects — learning and memory - PMID 27411820 Mixed
Nootropic effects — learning and memory - PMID 29798983 Mixed
Ischemic stroke — neuroprotection and functional recovery - PMID 30225715 Mixed
Nootropic effects — learning and memory - PMID 32342318 Mixed
Nootropic effects — learning and memory - PMID 32580520 Mixed
Ischemic stroke — neuroprotection and functional recovery - PMID 34201112 Mixed
Ischemic stroke — neuroprotection and functional recovery - PMID 35080861 Mixed
Alzheimer's disease — amyloid aggregation inhibition and cognitive improvement - PMID 40496623 Mixed
Alzheimer's disease — amyloid aggregation inhibition and cognitive improvement - PMID 41004910 Mixed
Neurodegenerative disease (general) — oxidative stress and neuroinflammation modulation - PMID 41479572 Mixed
Alzheimer's disease — amyloid aggregation inhibition and cognitive improvement - PMID 11443939
IC50 10 µM In vitro (in_vitro) - PMID 16996699 Animal studies only
Attention-deficit hyperactivity disorder (ADHD) and Rett syndrome — hypothesized therapeutic potenti - PMID 19145359 Animal studies only
Audiogenic epilepsy — neonatal intervention - PMID 19662538
- PMID 22708068 Animal studies only
Neonatal stress / maternal deprivation — behavioral correction - PMID 22772900
- PMID 22803132 Animal studies only
Neonatal stress / maternal deprivation — behavioral correction - PMID 23888777
- PMID 24385169 Animal studies only
Antidepressant / antistress effects - PMID 27586814
N-terminal acetylation of Semax (Ac-Semax) did not protect SH-SY5Y neuroblastoma cells from Cu(II)-induced cytotoxicity, unlike parent Semax — suggesting modifi - PMID 27921334
- PMID 28577097 Animal studies only
Stress-induced gastrointestinal and hepatic protection - PMID 28702721 Animal studies only
Parkinson's disease — behavioral effects - PMID 29577196
0.1 µM and 1 µM Perfusion solution (in vitro) (animal) - PMID 31028579 Animal studies only
Immunomodulation - PMID 32737723
5, 50, 150, 450 µg/kg Intraperitoneal (animal) - PMID 33418449 Animal studies only
Early-life SSRI exposure — behavioral and neurochemical correction - PMID 33459919 Animal studies only
Stress-induced gastrointestinal and hepatic protection - PMID 34097675
- PMID 38459919
5, 50, 150, 450 µg/kg Intraperitoneal (animal) - PMID 39442746 Animal studies only
Antidepressant / antistress effects - PMID 40692165 Animal studies only
Spinal cord injury — functional recovery - PMID 41171324
1 µM (in vitro/ex vivo slice preparation) Bath application (brain slice) (animal) - PMID 42021992
Non-approved peptide with limited long-term safety data and absence of systematic clinical validation noted in narrative review